High Affinity Fluorescent Probe for Proteinase-Activated Receptor 2 (PAR2)

被引:6
|
作者
LeSarge, Jordan C. [1 ]
Thibeault, Pierre [2 ]
Milne, Mark [5 ]
Ramachandran, Rithwik [2 ]
Luyt, Leonard G. [1 ,3 ,4 ,5 ]
机构
[1] Univ Western Ontario, Dept Chem, 1151 Richmond St, London, ON N6A 3K7, Canada
[2] Univ Western Ontario, Dept Physiol & Pharmacol, 1151 Richmond St, London, ON N6A 3K7, Canada
[3] Univ Western Ontario, Dept Oncol, 1151 Richmond St, London, ON N6A 3K7, Canada
[4] Univ Western Ontario, Dept Med Imaging, 1151 Richmond St, London, ON N6A 3K7, Canada
[5] Lawson Hlth Res Inst, London Reg Canc Program, 800 Commissioners Rd East, London, ON N6A 5W9, Canada
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 07期
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
Proteinase-activated receptor 2 (PAR2); peptide; targeted fluorescent probes; fluorescence imaging; structure-activity relationship; MOLECULAR-CLONING; EXPRESSION; POTENT; BINDING; PROTEASE-ACTIVATED-RECEPTOR-1; 2-FUROYL-LIGRLO-AMIDE; AGONISTS; PEPTIDE; GROWTH; CANCER;
D O I
10.1021/acsmedchemlett.9b00094
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
PAR2 is a proteolytically activated G protein coupled receptor (GPCR) that is implicated in various cancers and inflammatory diseases. Ligands with low nano molar affinity for PAR2 have been developed, but there is a paucity of research on the development of PAR2-targeting imaging probes. Here, we report the development of seven novel PAR2-targeting compounds. Four of these compounds are highly potent and selective PAR2-targeting peptides (EC50 = 10 to 23 nM) that have a primary amine handle available for facile conjugation to various imaging components. We describe a peptide of the sequence Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2 as the most potent and highest affinity PAR2-selective fluorescent probe reported to date (EC50 = 16 nM, K-D = 38 nM). This compound has a greater than 10-fold increase in potency and binding affinity for PAR2 compared to the leading previously reported probe and is conjugated to a red-shifted fluorophore, enabling in vitro and in vivo studies.
引用
收藏
页码:1045 / 1050
页数:11
相关论文
共 50 条
  • [1] Proteinase-activated Receptor 2 (PAR2) Decreases Apoptosis in Colonic Epithelial Cells
    Iablokov, Vadim
    Hirota, Christina L.
    Peplowski, Michael A.
    Ramachandran, Rithwik
    Mihara, Koichiro
    Hollenberg, Morley D.
    MacNaughton, Wallace K.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (49) : 34366 - 34377
  • [2] Proteinase-activated receptor 2 (PAR2) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level
    Kaufmann, Roland
    Hascher, Alexander
    Mussbach, Franziska
    Henklein, Petra
    Katenkamp, Kathrin
    Westermann, Martin
    Settmacher, Utz
    HISTOCHEMISTRY AND CELL BIOLOGY, 2012, 138 (06) : 913 - 924
  • [3] Neutrophil Elastase Acts as a Biased Agonist for Proteinase-activated Receptor-2 (PAR2)
    Ramachandran, Rithwik
    Mihara, Koichiro
    Chung, Hyunjae
    Renaux, Bernard
    Lau, Chang S.
    Muruve, Daniel A.
    DeFea, Kathryn A.
    Bouvier, Michel
    Hollenberg, Morley D.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (28) : 24638 - 24648
  • [4] Proteinase-activated receptor-2 (PAR2) and mouse osteoblasts: Regulation of cell function and lack of specificity of PAR2-activating peptides
    Georgy, Smitha R.
    Pagel, Charles N.
    Wong, David M.
    Sivagurunathan, Sutharshani
    Loh, Lay H.
    Myers, Damian E.
    Hollenberg, Morley D.
    Pike, Robert N.
    Mackie, Eleanor J.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (03) : 328 - 336
  • [5] Blockade of Proteinase-Activated Receptor 2 (PAR2) Attenuates Neuroinflammation in Experimental Autoimmune EncephalomyelitisS
    Eftekhari, Rahil
    Ewanchuk, Benjamin W.
    Rawji, Khalil S.
    Yates, Robin M.
    Noorbakhsh, Farshid
    Kuipers, Hedwich F.
    Hollenberg, Morley D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2024, 388 (01) : 12 - 22
  • [6] MicroRNA-205 Mediates Proteinase-Activated Receptor 2 (PAR2) -Promoted Cancer Cell Migration
    Yang, Xu
    Yang, Lan
    Ma, Yiming
    Zhao, Xinhua
    Wang, Hongying
    CANCER INVESTIGATION, 2017, 35 (09) : 601 - 609
  • [7] Proteinase-activated receptor-2 (PAR2) on blood pressure and electrolyte handling in the late pregnant rat
    West, David A., Jr.
    Beck, Steven D.
    de Souza, Aline M. A.
    West, Crystal A.
    EXPERIMENTAL PHYSIOLOGY, 2021, 106 (06) : 1373 - 1379
  • [8] Expression of Proteinase-activated Receptor 2 (PAR2) as a Correlate of Concern in Triple-negative Breast Cancer (TNBC)
    Kapatia, Gargi
    Kaur, Subhpreet
    Kumar, Sandeep
    Laroiya, Ishita
    Singh, Gurpreet
    Sharma, Maryada
    Bal, Amanjit
    Luthra-Guptasarma, Manni
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2022, 30 (06) : 446 - 452
  • [9] Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy
    Yu, Feng
    Huo, Hongjie
    Tang, Qiong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (05) : 397 - 410
  • [10] Mapping transmembrane residues of proteinase activated receptor 2 (PAR2) that influence ligand-modulated calcium signaling
    Suen, J. Y.
    Adams, M. N.
    Lim, J.
    Madala, P. K.
    Xu, W.
    Cotterell, A. J.
    He, Y.
    Yau, M. K.
    Hooper, J. D.
    Fairlie, D. P.
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 328 - 342